Genomically matched therapies targeting activated tyrosine kinases have shown promise across multiple cancer types.1 The success of tyrosine kinase inhibitors (TKIs) such as imatinib, a BCR‐ABL fusion protein inhibitor2; vemurafenib, a RAF inhibitor3; lapatinib, an inhibitor of ERBB24; erlotinib and crizotinib, inhibitors of EGFR and ALK, respectively5, 6; and, others have provided a powerful validation for precision cancer medicine. Here, ABL1 is linked to cancer.